The company expects approximately $200 million in gross proceeds before fees and expenses. In a later filing it said the placement closed on October 19, 2026.
First Tracks Biotherapeutics began trading on Nasdaq as AnaptysBio completed the spin-off. The release says the company launches with $180 million in cash and a two-year cash runway that it calls a projection, while the 8-K allocates $100.0 million in cash to First Tracks.
Shareholders received one First Tracks share for each AnaptysBio share held on April 6, 2026. AnaptysBio now manages two royalty collaborations and starts with about $140-$145 million in net cash.
AnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs.
Questions about First Tracks Biotherapeutics
What is the ticker symbol of First Tracks Biotherapeutics?
First Tracks Biotherapeutics, Inc. trades under the ticker TRAX on NASDAQ.
Where is First Tracks Biotherapeutics listed?
First Tracks Biotherapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:B43; LSX:A428R1.
What is the SEC CIK of First Tracks Biotherapeutics?
The SEC Central Index Key (CIK) for First Tracks Biotherapeutics, Inc. is 2091349. Its filings are on SEC EDGAR.
How many shares does First Tracks Biotherapeutics have outstanding?
35,730,843 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Which country or territory is First Tracks Biotherapeutics listed under?
Our directory records First Tracks Biotherapeutics, Inc. under United States.
What does First Tracks Biotherapeutics do?
Our directory classifies First Tracks Biotherapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of First Tracks Biotherapeutics?
The ISIN recorded for First Tracks Biotherapeutics, Inc. is US3371851029.
Does aibio.space cover First Tracks Biotherapeutics?
aibio.space lists First Tracks Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is First Tracks Biotherapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest First Tracks Biotherapeutics (TRAX) stock news?
Our latest story on First Tracks Biotherapeutics, dated Oct 15, 2026: "First Tracks Biotherapeutics agrees to sell 6,106,870 shares at $32.75, about $200 million". The company expects approximately $200 million in gross proceeds before fees and expenses. In a later filing it said the placement closed on October 19, 2026. Source.
What is First Tracks Biotherapeutics's latest stock offering or financing news?
Our latest financing story, dated Oct 15, 2026: "First Tracks Biotherapeutics agrees to sell 6,106,870 shares at $32.75, about $200 million". The company expects approximately $200 million in gross proceeds before fees and expenses. In a later filing it said the placement closed on October 19, 2026. Source.
Who were the underwriters or placement agents on First Tracks Biotherapeutics's offering?
From our story: Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities were placement agents. Source.
How long will First Tracks Biotherapeutics's cash last?
From our story of Apr 20, 2026: The release says the company launches with $180 million in cash and a two-year cash runway that it calls a projection, while the 8-K allocates $100.0 million in cash to First Tracks. Source.
How much cash does First Tracks Biotherapeutics have?
From our story of Apr 20, 2026: The release says the company launches with $180 million in cash and a two-year cash runway that it calls a projection, while the 8-K allocates $100.0 million in cash to First Tracks. Source.
Is First Tracks Biotherapeutics being acquired or merging?
Our latest merger story, dated Apr 20, 2026: "First Tracks Biotherapeutics begins Nasdaq trading after AnaptysBio spin-off". First Tracks Biotherapeutics began trading on Nasdaq as AnaptysBio completed the spin-off. The release says the company launches with $180 million in cash and a two-year cash runway that it calls a projection, while the 8-K allocates $100.0 million in cash to First Tracks. Source.
Investor discussion: First Tracks Biotherapeutics
Members talk about First Tracks Biotherapeutics (TRAX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at First Tracks Biotherapeutics, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.01,5.02,5.03,8.01,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:TRAX on TradingView.
SEC filings and registration
SEC name
First Tracks Biotherapeutics, Inc.
CIK
2091349
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
TRAX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
10770 WATERIDGE CIRCLE, SAN DIEGO, CA, 92121
Phone
212-373-3000
Shares outstanding
35,730,843 as of 2026-08-07 (10-Q filed 2026-08-12)
Former names
Biopharma Company, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
First Tracks Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TRAX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio